MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9842
-0.0358
-3.51%
Closed 19:51 07/08 EDT
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.030
LOW
0.9500
VOLUME
706.55K
TURNOVER
--
52 WEEK HIGH
2.250
52 WEEK LOW
0.4195
MARKET CAP
44.24M
P/E (TTM)
-1.2981
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SEEL stock price target is 8.00 with a high estimate of 12.00 and a low estimate of 4.000.

EPS

SEEL News

More
Seelos Therapeutics Reports Initiation Of Preclinical Study Of SLS-007 In Parkinson's Disease
Benzinga · 06/25 12:03
Seelos Therapeutics Announces Final Data from Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans
GlobeNewswire · 06/23 12:00
Seelos' intranasal ketamine shows favorable safety profile in early-stage study
Seeking Alpha - Article · 06/23 11:22
Seelos Therapeutics, Inc. (NASDAQ:SEEL): When Will It Breakeven?
Simply Wall St. · 06/17 14:08
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002
GlobeNewswire · 06/15 13:01
Hedge Funds Warming Up To Seelos Therapeutics, Inc. (SEEL)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inve
Insider Monkey · 06/04 23:26
Why Seelos Therapeutics Is Trading Higher Today
Seelos Therapeutics (NASDAQ: SEEL) shares are trading higher on Thursday after the company announced the initiation of a preclinical study of SLS-004 In Parkinson's Disease.
Benzinga · 05/28 15:03
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinsons Disease
GlobeNewswire · 05/28 12:01

Industry

Pharmaceuticals
+0.25%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About SEEL

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
More

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.